Literature DB >> 8153662

Imaging of gliomas.

T N Byrne1.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 8153662

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  27 in total

1.  Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Taryar Zaw; Albert Lai; Phioanh L Nghiemphu; Robert Harris; Shadi Lalezari; Naveed Wagle; Kourosh M Naeini; Jose Carrillo; Linda M Liau; Whitney B Pope
Journal:  Neuro Oncol       Date:  2012-01-22       Impact factor: 12.300

2.  Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas.

Authors:  Michail Plotkin; C Blechschmidt; G Auf; F Nyuyki; L Geworski; T Denecke; W Brenner; F Stockhammer
Journal:  Eur Radiol       Date:  2010-06-03       Impact factor: 5.315

3.  Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.

Authors:  Michail Plotkin; Holger Amthauer; Julia Eisenacher; Reinhard Wurm; Roger Michel; Peter Wust; Florian Stockhammer; Rainer Röttgen; Matthias Gutberlet; Juri Ruf; Roland Felix
Journal:  Neuroradiology       Date:  2005-01-04       Impact factor: 2.804

4.  Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma.

Authors:  K Lote; T Egeland; B Hager; K Skullerud; H Hirschberg
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

Review 5.  Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies.

Authors:  Nishant Verma; Matthew C Cowperthwaite; Mark G Burnett; Mia K Markey
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

6.  Pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT: does it have a place in predicting survival in patients with glioblastoma multiforme?

Authors:  Amr Amin; M Mustafa; E Abd El-Hadi; A Monier; A Badwey; E Saad
Journal:  J Neurooncol       Date:  2014-10-28       Impact factor: 4.130

7.  Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Albert Lai; Phioanh L Nghiemphu; Shadi Lalezari; Taryar Zaw; Kourosh Motevalibashinaeini; Paul S Mischel; Whitney B Pope
Journal:  J Neurooncol       Date:  2011-06-25       Impact factor: 4.130

8.  Clinical significance of thallium-201 SPECT after postoperative radiotherapy in patients with glioblastoma multiforme.

Authors:  Gyo Iida; Kazuhiko Ogawa; Shogo Ishiuchi; Itaru Chiba; Takashi Watanabe; Naofumi Katsuyama; Yoshihiko Yoshii; Sadayuki Murayama
Journal:  J Neurooncol       Date:  2010-09-02       Impact factor: 4.130

Review 9.  Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities.

Authors:  George A Alexiou; Spyridon Tsiouris; Athanasios P Kyritsis; Spyridon Voulgaris; Maria I Argyropoulou; Andreas D Fotopoulos
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

Review 10.  Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?

Authors:  Ashish H Shah; Brian Snelling; Amade Bregy; Payal R Patel; Danoushka Tememe; Rita Bhatia; Evelyn Sklar; Ricardo J Komotar
Journal:  J Neurooncol       Date:  2013-01-24       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.